QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited (QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce that Richard Godfrey will present to potential partners and investors at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through...
MojiaBio to hold Industrial Biomanufacturing Day at the AIChE Metabolic Engineering Conference in Singapore
SINGAPORE, May 31, 2023 /PRNewswire/ -- Mojia Biotech, a fast-growing biomanufacturing company specializing in the sustainable production of feed additives and bio-based materials, announces that it will hold an Industrial Biomanufacturing Day on June 15, 2023, following the AIChE Metabolic Engineering 15 Conference, to explore the latest developments in biomanufacturing, and how this rapidly growing field is transforming the...
Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023
SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago...
THINK Surgical’s TMINI Miniature Robotic System developed with Sagentia Innovation gains FDA 510(k) clearance
CAMBRIDGE, England, May 31, 2023 /PRNewswire/ -- THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). THINK Surgical's TMINI™ Miniature Robotic handpiece, developed in partnership with Sagentia Innovation. THINK Surgical chose R&D consultancy Sagentia Innovation, a market-leading advanced surgical robotics developer, to...
SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk cancer patients...
Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement
EAST RUTHERFORD, N.J, May 31, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new...
【 C.S 】: The first company with Cordyceps sinensis assets as the main body was successfully listed on the US SEC
TAIPEI, May 31, 2023 /PRNewswire/ -- Cordyceps, a Chinese medicinal material, is interestingly being called the "Winter Worm" in Chinese due to its unique physical appearance. The older generations may be familiar with this valuable herb for its effect in restoring energy, promoting longevity, and improving quality of life. However, the younger generations may not be aware of the worth...
Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC
SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is 325 million dollars, and it includes an upfront payment of 1.9 million...
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients
SHANGHAI, May 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, today announced the completion of patient enrollment in the Real-World Study ("RWS") conducted in the Boao Lecheng Pilot Zone in Hainan, China, to...
Waterdrop Inc. Announces Earnings Date Change: First Quarter 2023 Earnings Release Scheduled June 2, 2023
BEIJING, May 31, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2023, before U.S. markets open on Friday, June 2, 2023, instead of the previously announced date of June...
